1	Expression	_	NN	_	_	0	ROOT	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	thymidylate	_	NN	_	_	4	NMOD	_	_
4	synthase	_	NN	_	_	2	PMOD	_	_
5	and	_	CC	_	_	4	COORD	_	_
6	dihydropyrimidine	_	NN	_	_	7	NMOD	_	_
7	dehydrogenase	_	NN	_	_	5	CONJ	_	_
8	in	_	IN	_	_	1	NMOD	_	_
9	primary	_	JJ	_	_	13	NMOD	_	_
10	oral	_	JJ	_	_	13	NMOD	_	_
11	squamous	_	JJ	_	_	13	NMOD	_	_
12	cell	_	NN	_	_	13	NMOD	_	_
13	carcinoma	_	NN	_	_	8	PMOD	_	_
14	and	_	CC	_	_	13	COORD	_	_
15	corresponding	_	JJ	_	_	16	NMOD	_	_
16	metastases	_	NNS	_	_	14	CONJ	_	_
17	in	_	IN	_	_	13	NMOD	_	_
18	cervical	_	JJ	_	_	20	NMOD	_	_
19	lymph	_	NN	_	_	20	NMOD	_	_
20	nodes	_	NNS	_	_	17	PMOD	_	_
21	:	_	:	_	_	1	P	_	_
22	association	_	NN	_	_	1	APPO	_	_
23	with	_	IN	_	_	22	NMOD	_	_
24	the	_	DT	_	_	26	NMOD	_	_
25	metastasis	_	NN	_	_	26	NMOD	_	_
26	suppressor	_	NN	_	_	23	PMOD	_	_
27	CD82	_	CD	_	_	26	NMOD	_	_
28	.	_	.	_	_	1	P	_	_
		
1	Thymidylate	_	NN	_	_	2	NMOD	_	_
2	synthase	_	NN	_	_	12	VMOD	_	_
3	(	_	(	_	_	4	P	_	_
4	TS	_	NN	_	_	2	PRN	_	_
5	)	_	)	_	_	4	P	_	_
6	and	_	CC	_	_	2	COORD	_	_
7	dihydropyrimidine	_	NN	_	_	8	NMOD	_	_
8	dehydrogenase	_	NN	_	_	6	CONJ	_	_
9	(	_	(	_	_	10	P	_	_
10	DPD	_	NN	_	_	8	PRN	_	_
11	)	_	)	_	_	10	P	_	_
12	are	_	VBP	_	_	0	ROOT	_	_
13	5-fluorouracil	_	NN	_	_	18	NMOD	_	_
14	(	_	(	_	_	15	P	_	_
15	5-FU	_	NN	_	_	13	PRN	_	_
16	)	_	)	_	_	15	P	_	_
17	metabolizing	_	NN	_	_	18	NMOD	_	_
18	enzymes	_	NNS	_	_	12	VMOD	_	_
19	and	_	CC	_	_	12	COORD	_	_
20	are	_	VBP	_	_	19	CONJ	_	_
21	involved	_	VBN	_	_	20	VC	_	_
22	in	_	IN	_	_	21	VMOD	_	_
23	the	_	DT	_	_	24	NMOD	_	_
24	sensitivity	_	NN	_	_	22	PMOD	_	_
25	of	_	IN	_	_	24	NMOD	_	_
26	carcinoma	_	NN	_	_	27	NMOD	_	_
27	patients	_	NNS	_	_	25	PMOD	_	_
28	to	_	TO	_	_	24	NMOD	_	_
29	5-FU	_	NN	_	_	28	PMOD	_	_
30	.	_	.	_	_	12	P	_	_
		
1	Although	_	IN	_	_	14	VMOD	_	_
2	5-FU	_	NN	_	_	3	VMOD	_	_
3	is	_	VBZ	_	_	1	SUB	_	_
4	often	_	RB	_	_	3	VMOD	_	_
5	used	_	VBN	_	_	3	VC	_	_
6	for	_	IN	_	_	5	VMOD	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	treatment	_	NN	_	_	6	PMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	oral	_	JJ	_	_	11	NMOD	_	_
11	carcinoma	_	NN	_	_	9	PMOD	_	_
12	,	_	,	_	_	14	P	_	_
13	there	_	EX	_	_	14	VMOD	_	_
14	has	_	VBZ	_	_	0	ROOT	_	_
15	not	_	RB	_	_	14	VMOD	_	_
16	been	_	VBN	_	_	14	VC	_	_
17	any	_	DT	_	_	18	NMOD	_	_
18	investigation	_	NN	_	_	16	VMOD	_	_
19	into	_	IN	_	_	18	NMOD	_	_
20	the	_	DT	_	_	21	NMOD	_	_
21	expression	_	NN	_	_	19	PMOD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	these	_	DT	_	_	24	NMOD	_	_
24	enzymes	_	NNS	_	_	22	PMOD	_	_
25	in	_	IN	_	_	21	NMOD	_	_
26	metastatic	_	JJ	_	_	28	NMOD	_	_
27	lymph	_	NN	_	_	28	NMOD	_	_
28	nodes	_	NNS	_	_	25	PMOD	_	_
29	or	_	CC	_	_	25	COORD	_	_
30	of	_	IN	_	_	29	CONJ	_	_
31	their	_	PRP$	_	_	32	NMOD	_	_
32	roles	_	NNS	_	_	30	PMOD	_	_
33	in	_	IN	_	_	32	NMOD	_	_
34	the	_	DT	_	_	35	NMOD	_	_
35	effectiveness	_	NN	_	_	33	PMOD	_	_
36	of	_	IN	_	_	35	NMOD	_	_
37	5-FU	_	NN	_	_	36	PMOD	_	_
38	in	_	IN	_	_	35	NMOD	_	_
39	treating	_	VBG	_	_	38	PMOD	_	_
40	lymph	_	NN	_	_	42	NMOD	_	_
41	node-metastatic	_	JJ	_	_	42	NMOD	_	_
42	cancer	_	NN	_	_	39	VMOD	_	_
43	.	_	.	_	_	14	P	_	_
		
1	Oral	_	JJ	_	_	4	NMOD	_	_
2	squamous	_	JJ	_	_	4	NMOD	_	_
3	cell	_	NN	_	_	4	NMOD	_	_
4	carcinoma	_	NN	_	_	9	VMOD	_	_
5	(	_	(	_	_	6	P	_	_
6	OSCC	_	NN	_	_	4	PRN	_	_
7	)	_	)	_	_	6	P	_	_
8	often	_	RB	_	_	9	VMOD	_	_
9	metastasizes	_	VBZ	_	_	0	ROOT	_	_
10	to	_	TO	_	_	9	VMOD	_	_
11	the	_	DT	_	_	13	NMOD	_	_
12	lymph	_	NN	_	_	13	NMOD	_	_
13	nodes	_	NNS	_	_	10	PMOD	_	_
14	,	_	,	_	_	9	P	_	_
15	and	_	CC	_	_	9	COORD	_	_
16	these	_	DT	_	_	17	NMOD	_	_
17	enzymes	_	NNS	_	_	18	VMOD	_	_
18	may	_	MD	_	_	15	CONJ	_	_
19	be	_	VB	_	_	18	VC	_	_
20	significant	_	JJ	_	_	19	VMOD	_	_
21	in	_	IN	_	_	20	AMOD	_	_
22	the	_	DT	_	_	23	NMOD	_	_
23	survival	_	NN	_	_	21	PMOD	_	_
24	of	_	IN	_	_	23	NMOD	_	_
25	patients	_	NNS	_	_	24	PMOD	_	_
26	with	_	IN	_	_	25	NMOD	_	_
27	this	_	DT	_	_	28	NMOD	_	_
28	disease	_	NN	_	_	26	PMOD	_	_
29	.	_	.	_	_	9	P	_	_
		
1	This	_	DT	_	_	2	NMOD	_	_
2	study	_	NN	_	_	3	VMOD	_	_
3	investigated	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	expression	_	NN	_	_	3	VMOD	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	TS	_	NN	_	_	6	PMOD	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	DPD	_	NN	_	_	8	CONJ	_	_
10	in	_	IN	_	_	5	NMOD	_	_
11	cervical	_	JJ	_	_	13	NMOD	_	_
12	lymph	_	NN	_	_	13	NMOD	_	_
13	node	_	NN	_	_	14	NMOD	_	_
14	metastases	_	NNS	_	_	10	PMOD	_	_
15	and	_	CC	_	_	14	COORD	_	_
16	its	_	PRP$	_	_	17	NMOD	_	_
17	relationship	_	NN	_	_	15	CONJ	_	_
18	with	_	IN	_	_	17	NMOD	_	_
19	primary	_	JJ	_	_	20	NMOD	_	_
20	OSCC	_	NN	_	_	18	PMOD	_	_
21	,	_	,	_	_	5	P	_	_
22	as	_	RB	_	_	5	COORD	_	_
23	well	_	RB	_	_	22	DEP	_	_
24	as	_	IN	_	_	22	DEP	_	_
25	the	_	DT	_	_	26	NMOD	_	_
26	interaction	_	NN	_	_	22	CONJ	_	_
27	between	_	IN	_	_	26	NMOD	_	_
28	these	_	DT	_	_	29	NMOD	_	_
29	enzymes	_	NNS	_	_	27	PMOD	_	_
30	and	_	CC	_	_	29	COORD	_	_
31	Kangai	_	NNP	_	_	30	CONJ	_	_
32	1(KAI1/CD82)	_	CD	_	_	31	NMOD	_	_
33	which	_	WDT	_	_	34	VMOD	_	_
34	is	_	VBZ	_	_	29	NMOD	_	_
35	a	_	DT	_	_	38	NMOD	_	_
36	metastasis	_	NN	_	_	38	NMOD	_	_
37	suppressor	_	NN	_	_	38	NMOD	_	_
38	protein	_	NN	_	_	34	VMOD	_	_
39	.	_	.	_	_	3	P	_	_
		
1	Surgical	_	JJ	_	_	2	NMOD	_	_
2	specimens	_	NNS	_	_	28	VMOD	_	_
3	from	_	IN	_	_	2	NMOD	_	_
4	20	_	CD	_	_	5	NMOD	_	_
5	cases	_	NNS	_	_	3	PMOD	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	OSCC	_	NN	_	_	6	PMOD	_	_
8	with	_	IN	_	_	5	NMOD	_	_
9	lymph	_	NN	_	_	10	NMOD	_	_
10	node	_	NN	_	_	11	NMOD	_	_
11	metastasis	_	NN	_	_	8	PMOD	_	_
12	,	_	,	_	_	5	P	_	_
13	20	_	CD	_	_	14	NMOD	_	_
14	cases	_	NNS	_	_	5	COORD	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	OSCC	_	NN	_	_	15	PMOD	_	_
17	without	_	IN	_	_	14	NMOD	_	_
18	lymph	_	NN	_	_	19	NMOD	_	_
19	node	_	NN	_	_	20	NMOD	_	_
20	metastasis	_	NN	_	_	17	PMOD	_	_
21	,	_	,	_	_	14	P	_	_
22	and	_	CC	_	_	14	COORD	_	_
23	10	_	CD	_	_	24	NMOD	_	_
24	cases	_	NNS	_	_	22	CONJ	_	_
25	of	_	IN	_	_	24	NMOD	_	_
26	normal	_	JJ	_	_	27	NMOD	_	_
27	mucosa	_	NN	_	_	25	PMOD	_	_
28	were	_	VBD	_	_	0	ROOT	_	_
29	examined	_	VBN	_	_	28	VC	_	_
30	by	_	IN	_	_	29	VMOD	_	_
31	immunohistochemistry	_	NN	_	_	30	PMOD	_	_
32	.	_	.	_	_	28	P	_	_
		
1	The	_	DT	_	_	2	NMOD	_	_
2	relationship	_	NN	_	_	11	VMOD	_	_
3	between	_	IN	_	_	2	NMOD	_	_
4	TS	_	NN	_	_	3	PMOD	_	_
5	and	_	CC	_	_	4	COORD	_	_
6	DPD	_	NN	_	_	5	CONJ	_	_
7	expression	_	NN	_	_	6	COORD	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	clinicopathological	_	JJ	_	_	10	NMOD	_	_
10	data	_	NNS	_	_	8	CONJ	_	_
11	was	_	VBD	_	_	0	ROOT	_	_
12	analyzed	_	VBN	_	_	11	VC	_	_
13	.	_	.	_	_	11	P	_	_
		
1	TS	_	NN	_	_	5	VMOD	_	_
2	and	_	CC	_	_	1	COORD	_	_
3	DPD	_	NN	_	_	2	CONJ	_	_
4	proteins	_	NNS	_	_	3	COORD	_	_
5	were	_	VBD	_	_	0	ROOT	_	_
6	overexpressed	_	VBN	_	_	5	VC	_	_
7	in	_	IN	_	_	6	VMOD	_	_
8	primary	_	JJ	_	_	9	NMOD	_	_
9	OSCC	_	NN	_	_	7	PMOD	_	_
10	compared	_	VBN	_	_	6	VMOD	_	_
11	to	_	TO	_	_	10	PMOD	_	_
12	that	_	DT	_	_	11	PMOD	_	_
13	in	_	IN	_	_	12	NMOD	_	_
14	normal	_	JJ	_	_	15	NMOD	_	_
15	mucosa	_	NN	_	_	13	PMOD	_	_
16	.	_	.	_	_	5	P	_	_
		
1	TS	_	NN	_	_	2	NMOD	_	_
2	expression	_	NN	_	_	16	VMOD	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	the	_	DT	_	_	8	NMOD	_	_
5	primary	_	JJ	_	_	8	NMOD	_	_
6	oral	_	JJ	_	_	8	NMOD	_	_
7	cancer	_	NN	_	_	8	NMOD	_	_
8	cells	_	NNS	_	_	3	PMOD	_	_
9	in	_	IN	_	_	2	NMOD	_	_
10	the	_	DT	_	_	11	NMOD	_	_
11	group	_	NN	_	_	9	PMOD	_	_
12	with	_	IN	_	_	11	NMOD	_	_
13	lymph	_	NN	_	_	15	NMOD	_	_
14	node	_	NN	_	_	15	NMOD	_	_
15	metastasis	_	NN	_	_	12	PMOD	_	_
16	was	_	VBD	_	_	0	ROOT	_	_
17	higher	_	JJR	_	_	16	VMOD	_	_
18	than	_	IN	_	_	17	AMOD	_	_
19	that	_	DT	_	_	18	PMOD	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	those	_	DT	_	_	20	PMOD	_	_
22	without	_	IN	_	_	21	NMOD	_	_
23	.	_	.	_	_	16	P	_	_
		
1	DPD	_	NN	_	_	2	NMOD	_	_
2	expression	_	NN	_	_	3	VMOD	_	_
3	did	_	VBD	_	_	0	ROOT	_	_
4	not	_	RB	_	_	3	VMOD	_	_
5	significantly	_	RB	_	_	3	VMOD	_	_
6	correlate	_	VB	_	_	3	VC	_	_
7	with	_	IN	_	_	6	VMOD	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	occurrence	_	NN	_	_	7	PMOD	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	lymph	_	NN	_	_	13	NMOD	_	_
12	node	_	NN	_	_	13	NMOD	_	_
13	metastasis	_	NN	_	_	10	PMOD	_	_
14	,	_	,	_	_	3	P	_	_
15	nor	_	CC	_	_	3	COORD	_	_
16	was	_	VBD	_	_	15	CONJ	_	_
17	it	_	PRP	_	_	18	AMOD	_	_
18	different	_	JJ	_	_	16	VMOD	_	_
19	between	_	IN	_	_	18	AMOD	_	_
20	primary	_	JJ	_	_	23	NMOD	_	_
21	oral	_	JJ	_	_	23	NMOD	_	_
22	cancer	_	NN	_	_	23	NMOD	_	_
23	cells	_	NNS	_	_	19	PMOD	_	_
24	and	_	CC	_	_	23	COORD	_	_
25	cervical	_	JJ	_	_	26	NMOD	_	_
26	metastases	_	NNS	_	_	24	CONJ	_	_
27	.	_	.	_	_	3	P	_	_
		
1	CD82	_	CD	_	_	2	NMOD	_	_
2	expression	_	NN	_	_	3	VMOD	_	_
3	was	_	VBD	_	_	0	ROOT	_	_
4	significantly	_	RB	_	_	3	VMOD	_	_
5	reduced	_	VBN	_	_	3	VC	_	_
6	in	_	IN	_	_	5	VMOD	_	_
7	lymph	_	NN	_	_	9	NMOD	_	_
8	node	_	NN	_	_	9	NMOD	_	_
9	metastases	_	NNS	_	_	6	PMOD	_	_
10	.	_	.	_	_	3	P	_	_
		
1	These	_	DT	_	_	2	NMOD	_	_
2	findings	_	NNS	_	_	3	VMOD	_	_
3	indicate	_	VBP	_	_	0	ROOT	_	_
4	that	_	IN	_	_	3	VMOD	_	_
5	TS	_	NN	_	_	8	VMOD	_	_
6	and	_	CC	_	_	5	COORD	_	_
7	CD82	_	NN	_	_	6	CONJ	_	_
8	may	_	MD	_	_	4	SUB	_	_
9	be	_	VB	_	_	8	VC	_	_
10	of	_	IN	_	_	9	VMOD	_	_
11	great	_	JJ	_	_	12	NMOD	_	_
12	value	_	NN	_	_	10	PMOD	_	_
13	in	_	IN	_	_	9	VMOD	_	_
14	assessing	_	VBG	_	_	13	PMOD	_	_
15	lymph	_	NN	_	_	16	NMOD	_	_
16	node	_	NN	_	_	17	NMOD	_	_
17	metastasis	_	NN	_	_	14	VMOD	_	_
18	of	_	IN	_	_	17	NMOD	_	_
19	OSCC	_	NN	_	_	18	PMOD	_	_
20	,	_	,	_	_	8	P	_	_
21	and	_	CC	_	_	8	COORD	_	_
22	could	_	MD	_	_	21	CONJ	_	_
23	be	_	VB	_	_	22	VC	_	_
24	taken	_	VBN	_	_	23	VC	_	_
25	as	_	IN	_	_	24	VMOD	_	_
26	new	_	JJ	_	_	27	NMOD	_	_
27	targets	_	NNS	_	_	25	PMOD	_	_
28	for	_	IN	_	_	27	NMOD	_	_
29	therapy	_	NN	_	_	28	PMOD	_	_
30	of	_	IN	_	_	29	NMOD	_	_
31	metastatic	_	JJ	_	_	32	NMOD	_	_
32	OSCC	_	NN	_	_	30	PMOD	_	_
33	.	_	.	_	_	3	P	_	_
		
